Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -0.25% | -0.96% | +45.25% | +102.76% | 68.52B | |
| -1.09% | -4.97% | +31.10% | +76.56% | 62.88B | |
| -1.18% | +0.51% | -13.53% | +384.69% | 28.13B | |
| -2.74% | -3.53% | +26.13% | +13.50% | 25.56B | |
| -1.76% | -7.14% | -5.57% | -19.75% | 24.65B | |
| -2.39% | -4.23% | +18.42% | -20.95% | 19.81B | |
| -1.86% | +1.15% | +205.44% | +353.89% | 17.69B | |
| -1.37% | -3.77% | -9.38% | +528.34% | 14.66B | |
| -1.54% | -1.88% | +50.03% | +159.75% | 14.45B | |
| Average | -1.41% | -1.33% | +38.65% | +175.42% | 30.71B | |
| Weighted average by Cap. | -1.28% | -1.41% | +35.43% | +139.07% |
Employees
51
